ASH 2025 | A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combined venetoclax and inotuzumab ozogamicin for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Dr Luskin highlights the potential of this combination to improve the depth and durability of response for patients, thereby bridging them to consolidation therapies with curative potential. Dr Luskin notes that the combination was feasible to deliver with a manageable safety profile and encouraging responses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
